Australian Centre for Sexual Health, St Leonards, New South Wales, Australia.
J Sex Med. 2011 Feb;8(2):524-39. doi: 10.1111/j.1743-6109.2010.02097.x. Epub 2010 Nov 8.
Dapoxetine has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies in various populations worldwide and has recently been approved in several countries.
To present integrated efficacy and safety data from phase 3 trials of dapoxetine.
Data were from five randomized, multicenter, double-blind, placebo-controlled studies conducted in over 25 countries. Men (N=6,081)≥18 years who met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision criteria for PE; four studies required a baseline intravaginal ejaculatory latency time (IELT) of ≤2 minutes. Dapoxetine 30 and 60 mg on demand (prn; 1-3 hours before intercourse) were evaluated for either 12 or 24 weeks in four studies; one study evaluated dapoxetine 60 mg daily (qd; included in safety assessments only) or prn for 9 weeks.
End points included stopwatch-measured IELT, Premature Ejaculation Profile (PEP) items, clinical global impression of change (CGIC) in PE, and adverse events (AEs).
Average IELT (mean [standard deviation], geometric mean [standard error]) increased from baseline (across groups, 0.9 [0.49] minutes, 0.8 [1.01] minutes) to a significantly greater extent with dapoxetine 30 (3.1 [3.91] minutes, 2.0 [1.03] minutes) and 60 mg (3.6 [3.85] minutes, 2.3 [1.03] minutes) vs. placebo (1.9 [2.43] minutes, 1.3 [1.02] minutes; P<0.001 for all) at week 12 (geometric mean fold increase, 2.5, 3.0, and 1.6, respectively). All PEP items and CGIC improved significantly with both doses of dapoxetine vs. placebo (P<0.001 for all). The most common AEs included nausea, dizziness, and headache, and evaluation of validated instruments demonstrated no anxiety, akathisia, suicidality, or changes in mood with dapoxetine use and no discontinuation syndrome following abrupt withdrawal.
In this diverse population, dapoxetine significantly improved all aspects of PE and was generally well tolerated.
达泊西汀已在全球多个国家/地区的五项 3 期研究中评估按需治疗早泄(PE)的疗效,并已在多个国家/地区获得批准。
介绍达泊西汀 3 期临床试验的综合疗效和安全性数据。
数据来自全球 25 个以上国家进行的五项随机、多中心、双盲、安慰剂对照研究。年龄≥18 岁,符合《精神障碍诊断与统计手册》第 4 版修订版(DSM-IV-TR)PE 标准的男性;四项研究要求基线阴道内射精潜伏期时间(IELT)≤2 分钟。达泊西汀 30mg 和 60mg 按需(prn;性交前 1-3 小时)在四项研究中评估 12 或 24 周;一项研究评估达泊西汀 60mg 每日(qd;仅包含安全性评估)或 prn 9 周。
终点包括秒表测量的 IELT、早泄评估问卷(PEP)项目、PE 的临床总体印象变化(CGIC)和不良事件(AE)。
平均 IELT(均值[标准差],几何均数[标准误差])从基线(各组为 0.9[0.49]分钟,0.8[1.01]分钟)显著增加,与安慰剂相比,达泊西汀 30mg(3.1[3.91]分钟,2.0[1.03]分钟)和 60mg(3.6[3.85]分钟,2.3[1.03]分钟)有显著差异(P<0.001);在第 12 周(几何均数倍数增加,分别为 2.5、3.0 和 1.6)。所有 PEP 项目和 CGIC 均显著改善,达泊西汀优于安慰剂(P<0.001)。最常见的 AE 包括恶心、头晕和头痛,使用达泊西汀评估验证工具未发现焦虑、静坐不能、自杀意念或情绪变化,以及突然停药后无撤药综合征。
在这一多样化人群中,达泊西汀显著改善了所有 PE 方面的问题,且通常具有良好的耐受性。